Sugammadex

ApprovedCompleted

2 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Coronary Artery Bypass Graft and/or Aortic Valve Replacement Surgery

Conditions

Coronary Artery Bypass Graft and/or Aortic Valve Replacement Surgery

Trial Timeline

May 13, 2017 → Oct 10, 2020

NCT ID

NCT03196167

About Sugammadex

Sugammadex is a approved stage product being developed by Merck for Coronary Artery Bypass Graft and/or Aortic Valve Replacement Surgery. The current trial status is completed. This product is registered under clinical trial identifier NCT03196167. Target conditions include Coronary Artery Bypass Graft and/or Aortic Valve Replacement Surgery.

What happened to similar drugs?

20 of 20 similar drugs in Coronary Artery Bypass Graft and/or Aortic Valve Replacement Surgery were approved

Approved (20) Terminated (2) Active (0)

✅EvolocumabHeartFlowApproved

✅Clopidogrel treatment groupYuhanApproved

✅high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibeYuhanApproved

✅statins, ezetimibe + Combination therapyYuhanApproved

✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved

✅PrasugrelDaiichi SankyoApproved

✅Prasugrel + ClopidogrelDaiichi SankyoApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05276804	Phase 3	Completed	Apr 13, 2022	Sep 3, 2024	Postoperative Urinary Retention
NCT03196167	Approved	Completed	May 13, 2017	Oct 10, 2020	Coronary Artery Bypass Graft and/or Aortic Valve Replacement Surgery
NCT02011490	Phase 1	Completed	Dec 11, 2013	Jun 6, 2014	Renal Insufficiency
NCT00826176	Phase 3	Completed	Jan 1, 2010	Aug 1, 2010	Anesthesia, General
NCT00702715	Phase 3	Completed	Sep 24, 2008	Mar 15, 2010	Anesthesia
NCT00535496	Phase 3	Completed	Sep 1, 2007	Feb 1, 2008	Neuromuscular Blockade
NCT00591786	Phase 2	Completed	Dec 5, 2005	Oct 19, 2006	Anesthesia, General
NCT00552929	Phase 2	Completed	Oct 4, 2005	Sep 15, 2006	Anesthesia, General
NCT00482599	Phase 3	Completed	Jun 1, 2005	Apr 13, 2006	Anesthesia, General

Competing Products

20 competing products in Coronary Artery Bypass Graft and/or Aortic Valve Replacement Surgery

See all competitors

Product	Company	Stage	Hype Score
Rosuvastatin 40mg + Placebo	HeartFlow	Pre-clinical	27
Evolocumab	HeartFlow	Approved	29
High intensity lipid lowering	HeartFlow	Pre-clinical	20
Exenatide	Eli Lilly	Phase 3	40
Clopidogrel treatment group	Yuhan	Approved	50
YH14659 + clopidogrel & aspirin	Yuhan	Phase 1	29
high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibe	Yuhan	Approved	43
Sarpogrelate + Aspirin + Clopidogrel + Placebo (for Sarpogrelate)	Yuhan	Phase 3	40
statins, ezetimibe + Combination therapy	Yuhan	Approved	50
YH14659 + clopidogrel & aspirin	Yuhan	Phase 1	29
Modification of Prasugrel based on a biological assay + prasugrel / clopidogrel	Daiichi Sankyo	Approved	43
clopidogrel + prasugrel	Daiichi Sankyo	Phase 1	21
Prasugrel	Daiichi Sankyo	Approved	43
ADP receptor inhibitors	Daiichi Sankyo	Pre-clinical	26
Pactimibe, CS-505	Daiichi Sankyo	Phase 2	35
Prasugrel + Clopidogrel	Daiichi Sankyo	Phase 2	35
prasugrel + clopidogrel	Daiichi Sankyo	Phase 1	29
Prasugrel + Clopidogrel	Daiichi Sankyo	Approved	43
Triple oral lipid lowering treatment	Daiichi Sankyo	Phase 3	47
Placebo + Prasugrel	Daiichi Sankyo	Phase 3	40